Bedoukian   RussellIPM   RussellIPM   Piezoelectric Micro-Sprayer


Home
Animal Taxa
Plant Taxa
Semiochemicals
Floral Compounds
Semiochemical Detail
Semiochemicals & Taxa
Synthesis
Control
Invasive spp.
References

Abstract

Guide

Alphascents
Pherobio
InsectScience
E-Econex
Counterpart-Semiochemicals
Print
Email to a Friend
Kindly Donate for The Pherobase

« Previous Abstract"Emission of volatile organic compounds from composting: A review on assessment, treatment and perspectives"    Next AbstractIntegrated metabolome and transcriptome analysis of Magnolia champaca identifies biosynthetic pathways for floral volatile organic compounds »

Respir Care


Title:Inhaled Drug Therapy 2016: The Year in Review
Author(s):Dhand R;
Address:"Department of Medicine, University of Tennessee Graduate School of Medicine, Knoxville, Tennessee. RDhand@utmck.edu"
Journal Title:Respir Care
Year:2017
Volume:20170530
Issue:7
Page Number:978 - 996
DOI: 10.4187/respcare.05624
ISSN/ISBN:1943-3654 (Electronic) 0020-1324 (Linking)
Abstract:"Some recent salient publications related to inhaled drug therapy are discussed. Unexpectedly, a 2.5-mug once-daily dose of tiotropium (Respimat) had greater efficacy than the 5.0-mug daily dose. Occurrence of a reverse dose response serves to caution us that administering more drug is not always beneficial. Small-airway inflammation contributes to pathogenesis of asthma, especially severe asthma. However, there is no conclusive evidence that the use of small-particle aerosols to target small airways improves clinical outcomes in controlled clinical trials. Clinical outcomes of patients with symptomatic asthma have been better in 'real-life' studies when fine-particle aerosols were compared with conventional (large-particle) aerosols. In subjects with COPD, the FLAME study indicates that a long-acting antimuscarinic agent/long-acting beta-agonist combination was superior to an inhaled corticosteroid/long-acting beta-agonist combination in preventing exacerbations. Another study in children with asthma and adults with asthma or COPD showed that peak inhalation flow must be considered in the context of the dry powder inhaler resistance. Investigators from the United Kingdom have shown modest success in replacing the defective cystic fibrosis transmembrane regulator gene in subjects with cystic fibrosis with a plasmid encoding the normal cystic fibrosis transmembrane regulator gene packaged within a non-viral vector. Also, inhaled antibiotics in patients with non-cystic fibrosis bronchiectasis and inhaled interferon-gamma in patients with idiopathic pulmonary fibrosis have shown encouraging results but are investigational at this time. Compared to combustion cigarettes, use of e-cigarettes reduces exposure to carcinogens and volatile organic compounds. However, high levels of benzaldehyde in the vapor from cherry-flavored cigarettes raise concerns about the safety of some food flavorings in e-cigarettes"
Keywords:"*Administration, Inhalation Adult Aerosols/administration & dosage Bronchodilator Agents/*administration & dosage Child Dry Powder Inhalers Electronic Nicotine Delivery Systems Humans Lung Diseases/*drug therapy Copd aerosols asthma bronchiectasis cystic;"
Notes:"MedlineDhand, Rajiv eng Review 2017/06/01 Respir Care. 2017 Jul; 62(7):978-996. doi: 10.4187/respcare.05624. Epub 2017 May 30"

 
Back to top
 
Citation: El-Sayed AM 2024. The Pherobase: Database of Pheromones and Semiochemicals. <http://www.pherobase.com>.
© 2003-2024 The Pherobase - Extensive Database of Pheromones and Semiochemicals. Ashraf M. El-Sayed.
Page created on 22-11-2024